{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:17:00Z","timestamp":1762867020966,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.endinu.2018.05.015","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T09:22:29Z","timestamp":1533115349000},"page":"108-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efectos agudos y a largo plazo del tratamiento con zolendronato en pacientes adultos con osteog\u00e9nesis imperfecta. Estudio espa\u00f1ol observacional con 5 a\u00f1os de seguimiento"],"prefix":"10.1016","volume":"66","author":[{"given":"Isabel","family":"Pav\u00f3n de Paz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Rosado Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"P\u00e9rez Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiara","family":"Modro\u00f1o M\u00f3stoles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guadalupe","family":"Guijarro de Armas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Navea Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.endinu.2018.05.015_bib0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0065-3101(24)00183-X","article-title":"Osteogenesis imperfecta: comprehensive management","volume":"35","author":"Marini","year":"1988","journal-title":"Adv Pediatr."},{"key":"10.1016\/j.endinu.2018.05.015_bib0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2431-4-16","article-title":"Syndromes with congenital brittle bones","volume":"4","author":"Plotkin","year":"2004","journal-title":"BMC Pediatr."},{"issue":"6","key":"10.1016\/j.endinu.2018.05.015_bib0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJM198408093110606","article-title":"Heritable diseases of collagen","volume":"311","author":"Prockop","year":"1984","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.endinu.2018.05.015_bib0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18388\/abp.2002_3802","article-title":"Mutations in type I collagen genes resulting in osteogenesis imperfecta in humans","volume":"49","author":"Gajko-Galicka","year":"2002","journal-title":"Acta Biochim Pol."},{"key":"10.1016\/j.endinu.2018.05.015_bib0180","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effect of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3 year randomized placebo controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.endinu.2018.05.015_bib0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-001-1055-5","article-title":"The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with Type IA osteogenesis imperfecta","volume":"72","author":"Shapiro","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.endinu.2018.05.015_bib0190","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous noredronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.endinu.2018.05.015_bib0195","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","article-title":"Intravenous biphosphonates therapy increases radial width in adults with osteogenesis imperfecta","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.endinu.2018.05.015_bib0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.endonu.2010.03.017","article-title":"Efectos del tratamiento con \u00e1cido zoledr\u00f3nico en pacientes adultos con osteog\u00e9nesis imperfecta","volume":"57","author":"Pav\u00f3n de Paz","year":"2010","journal-title":"Endocrinol Nutr."},{"key":"10.1016\/j.endinu.2018.05.015_bib0205","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3928\/01477447-20161006-04","article-title":"Challenges of fracture management for adults with osteogenesis imperfecta","volume":"40","author":"Gil","year":"2017","journal-title":"Orthopedics."},{"key":"10.1016\/j.endinu.2018.05.015_bib0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1172\/JCI74230","article-title":"Osteogenesis imperfecta in adults","volume":"124","author":"Bishop","year":"2014","journal-title":"J Clin Invest."},{"key":"10.1016\/j.endinu.2018.05.015_bib0215","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11926-006-0044-0","article-title":"Osteog\u00e9nesis imperfecta: new treatment options","volume":"8","author":"Chevrel","year":"2006","journal-title":"Curr Rheumatol Rep."},{"key":"10.1016\/j.endinu.2018.05.015_bib0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2016.02.013","article-title":"Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial","volume":"86","author":"Plante","year":"2016","journal-title":"Bone."},{"key":"10.1016\/j.endinu.2018.05.015_bib0225","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Ciclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.endinu.2018.05.015_bib0230","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.endinu.2018.05.015_bib0235","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1067\/mpd.2003.137","article-title":"Treatment of sintomatic pediatric osteoporosis with ciclic single day intravenous pamidronate infusi\u00f3n","volume":"142","author":"Steelman","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.endinu.2018.05.015_bib0240","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.arcped.2009.03.008","article-title":"Biphosphonates and osteog\u00e9nesis imperfecta in children","volume":"16","author":"Gandon-Laloum","year":"2009","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.endinu.2018.05.015_bib0245","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risendronate in children with osteogenesis imperfecta: a randomized, double-blind, placebo-controlled trial","volume":"382","author":"Bisop","year":"2013","journal-title":"Lancet"},{"issue":"Issue 10.","key":"10.1016\/j.endinu.2018.05.015_bib0250","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2016","journal-title":"Cochrane database of systematic Reviews"},{"key":"10.1016\/j.endinu.2018.05.015_bib0255","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1021\/jm020819i","article-title":"Highly potent geminal biphophonates From pamidronate disodium to zoledronic acid","volume":"45","author":"Widdler","year":"2002","journal-title":"J Med Chem."},{"key":"10.1016\/j.endinu.2018.05.015_bib0260","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of posmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endinu.2018.05.015_bib0265","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/14656566.3.7.1007","article-title":"Zolendronate once-yearly increases bone mineral density-implications for osteoporosis","volume":"3","author":"Doggrell","year":"2002","journal-title":"Expert Opin Pharmacother."},{"key":"10.1016\/j.endinu.2018.05.015_bib0270","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risendronate in theprevention and treatment of glucocorticoid induced osteoporosis (HORIZON): a multicentre, double blind double dummy, randomisd, controlled trial","volume":"376","author":"Reid","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.endinu.2018.05.015_bib0275","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00277-006-0136-y","article-title":"Intravenous zoledronic acid treatment in talasemia-induced osteoporosis: results of a phase II clinical trial","volume":"85","author":"Otrock","year":"2006","journal-title":"Ann Hematol."},{"key":"10.1016\/j.endinu.2018.05.015_bib0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002512-200320030-00002","article-title":"Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer","volume":"20","author":"Smith","year":"2003","journal-title":"Drug Aging."},{"key":"10.1016\/j.endinu.2018.05.015_bib0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","article-title":"Intravenous neridronate in adults with osteogenesis imperfecta","volume":"18","author":"Adami","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.endinu.2018.05.015_bib0290","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00223-017-0236-9","article-title":"Long-term effects of neridronate in adults with osteogenesis imperfecta: an observational three years italian study","volume":"100","author":"Viapiana","year":"2017","journal-title":"Calcif Tissue Intern."},{"key":"10.1016\/j.endinu.2018.05.015_bib0295","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00223-010-9383-y","article-title":"Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta","volume":"87","author":"Shapiro","year":"2010","journal-title":"Calcif Tissue Int."},{"key":"10.1016\/j.endinu.2018.05.015_bib0300","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4158\/EP151184.OR","article-title":"The clinical characteristics and efficacy of biphosphonates in adult patients with osteogenesis imperfecta","volume":"22","author":"Xu","year":"2016","journal-title":"Endocr Pract."},{"key":"10.1016\/j.endinu.2018.05.015_bib0305","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact."},{"issue":"2","key":"10.1016\/j.endinu.2018.05.015_bib0310","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest."}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418301526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530016418301526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:04:57Z","timestamp":1762866297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530016418301526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S2530016418301526"],"URL":"https:\/\/doi.org\/10.1016\/j.endinu.2018.05.015","relation":{},"ISSN":["2530-0164"],"issn-type":[{"type":"print","value":"2530-0164"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos agudos y a largo plazo del tratamiento con zolendronato en pacientes adultos con osteog\u00e9nesis imperfecta. Estudio espa\u00f1ol observacional con 5 a\u00f1os de seguimiento","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endinu.2018.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEEN y SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}